Search Results
Results found for "Karuna Therapeutics"
- Dr. Lauren M. Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- The Practical Assessment of Signaling Bias | Dr. GPCR Ecosystem
. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes
- Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma
of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar | Dr. GPCR Ecosystem
This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream He and his artist/designer wife, Karina Åberg, have three teenage children.
- How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem
Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.
- Celtarys Research | Dr. GPCR Ecosystem
Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Dr. Terry Hébert | Dr. GPCR Ecosystem
Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University
- Dopamine-Mediated Motor Recovery after Ischemic Stroke
We hope our research will aid in the development of new therapeutic interventions for the alleviation
- Using-iPSC-derived-models-to-study-GPCR-function | Dr. GPCR Ecosystem
Introduction Drug discovery pipelines increasingly depend on screening platforms designed to identify therapeutically
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Illuminating Functional Selectivity and Allosterism at GPCRs.
He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director
- Targeting adenosine signaling for immuno-oncology
clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics
- Dr. Amynah Pradhan | Dr. GPCR Ecosystem
Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic
- Dr. Fiona Marshall | Dr. GPCR Ecosystem
As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Dr. Brian Arey | Dr. GPCR Ecosystem
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Dr. Aaron Sato | Dr. GPCR Ecosystem
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Dr. Brian Arey | Dr. GPCR Ecosystem
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Distinct sub-cellular signal propagation as a component of functional selectivity
of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Kevin Pfleger | Dr. GPCR Ecosystem
Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
- Structure Based Design of Modulators of Purinergic GPCRs | Dr. GPCR Ecosystem
His research focuses on developing computational pipelines for rational ligand design targeting therapeutically
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).


























